ArticleJournal of interventional cardiac electrophysiology : an international journal of arrhythmias and pacing2026
Preprocedural M2-muscarinic acetylcholine receptor autoantibody levels predict left atrial low-voltage area severity in atrial fibrillation undergoing catheter ablation.
Article in Journal of interventional cardiac electrophysiology : an international journal of arrhythmias and pacing, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
13 authors.
Funding
Abstract
backgroundAutoantibodies against the M2-muscarinic acetylcholine receptor (anti-M2-R) have been implicated in atrial remodeling and atrial fibrillation (AF) pathogenesis. However, their relationship with atrial fibrosis severity, as assessed by low-voltage areas (LVAs), remains unclear.
methodsThis prospective study included 164 patients (89 with paroxysmal AF [PAF], 75 with non-paroxysmal AF [NPAF]) undergoing first-time catheter ablation. Preprocedural plasma anti-M2-R levels were measured using ELISA. Left atrial LVAs were assessed via electroanatomic voltage mapping and categorized into four stages. Patients were grouped as having mild (≤ 20%) or moderate-to-extensive (>20%) LVA burden. Logistic regression and ROC curve analysis were used to evaluate predictors of LVA extent.
resultsThe anti-M2-R levels were significantly higher in NPAF patients than in PAF patients (282.8 ± 83.8 vs. 250.7 ± 74.2 ng/mL; p = 0.011). Patients with a moderate-to-extensive LVA size had higher anti-M2-R levels than those with mild LVA size (327.7 ± 85.1 vs. 251.4 ± 74.3 ng/mL; p < 0.001). In multivariate analysis, the anti-M2-R levels were significant predictor of moderate-to-extensive LVA size(OR per 10 ng/mL increase: 1.12; 95% CI: 1.05-1.20; p < 0.001). ROC analysis identified a cutoff value of 309.3 ng/mL for predicting extensive LVA (AUC: 0.75; sensitivity: 63%; specificity: 81%).
conclusionsThe preprocedural plasma anti-M2-R levels are independently associated with left atrial LVA severity in patients with AF and may serve as a minimally invasive biomarker for identifying patients with advanced atrial substrate, thereby guiding individualized ablation strategies.
Indexed as
Identifiers
41258271What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.